key: cord-0874408-n324scia
authors: Avogaro, Angelo; Bonora, Benedetta Maria; Fadini, Gian Paolo
title: Response to Chia Siang Kow and colleagues
date: 2022-01-13
journal: Acta Diabetol
DOI: 10.1007/s00592-021-01811-w
sha: 2d7dff2fe0a95d8f457fe3948d62af7805397abb
doc_id: 874408
cord_uid: n324scia

nan

We thank Chia Siang Kow and colleagues for their thoughtful considerations on our narrative review on diabetes treatment in patients with COVID-19 infection [1] . They point out that we did not include the sliding scale insulin treatment approach among the possible options for hospitalized patients. First of all, we fully agree that the inpatient blood glucose levels should also be considered when deciding the insulin regimen for hospitalized patients with diabetes. In our view, we also believe that sliding scale insulin can be a potential option for patients without significantly elevated blood glucose levels [2] . However, in most cases, the sliding scale insulin approach is performed by non-endocrinologists, who are not aware of the risks of the sliding scale approach, such as hyperglycemic episodes [3] . Although the hypoglycemic risk is slightly higher with the basal-bolus approach, this strategy is by far more physiological in terms of insulin concentrations and bioavailability. Moreover, we should anticipate rather than following hyperglycemia. Thus, we do not want to demonize the sliding scale approach, but this must be the exception and not the rule [4] .

Managing diabetes in diabetic patients with COVID: Where do we start from?

Umpierrez GE (2021) Inpatient glycemic control with sliding scale insulin in noncritical patients with type 2 diabetes: Who can slide?

Sliding scale insulin for non-critically ill hospitalized adults with diabetes mellitus

Things we do for no reason: sliding-scale insulin as monotherapy for glycemic control in hospitalized patients

Acknowledgements None.